China Health Group is a global leading full service provider of API and formulation development, clinical trial and product registration to pharmaceutical and biotechnology companies in China market and beyond. China Health Group is a Hong Kong public listed company (Stock Code: 8225.HK).
Since the inception of Venturepharm (china) in 1999, with the strong background of 7 VSmart® drug delivery platforms, the company has over 400 non-patent infringed products approved, pending or under development and 6 NCE before clinical stages, encompassing over 10 major therapeutic areas.
In the past year, China Health Group has been appraised by FORTUNE magazine as one of five most promising companies in China for the future.
The company's core competency is new drug R&D, driven by a force of over 300 international scientists and an extensive network of international and domestic specialists with a number of credentials in outsourced fully integrated pharmaceutical services which includes new drug research, drug delivery development, clinical research, product registration and sales and marketing.
The company has established a network of R&D and manufacturing facilities throughout the world, consisted of 8 R&D centers, 3 GMP integrated manufacture facilities and 4 bulk API manufacturing facilities, two of them are approved & USFDA inspected.
Pharmaceutical companies are much relying on outsourcing to help them meet growing demand and bring new drugs to market more economically and quickly. The world turns focus for this regard to China and other Asian countries to capture the opportunities for outsourcing of integrated pharmaceutical development in China.
China Health Group have adopted multi-growth engines strategy for high speed and long-term growth of company. This strategy is employed of multi-revenue models for confronting the realty to diversify the risk and maximizing the profits from all business cycles. We structured the company into five business units, VP-Technology Transfer, VP-PDS (Pharmaceutical Development Service), VP-CRS (Clinical Research Service), VP-API (Active Pharmaceutical Ingredient) and VP-Mart (Venturepharm-Mart) and they span from molecule sources stage of pharmaceutical value chain to commercialization of products to form a full service company. With core competency of R&D capability at sources of value chain, each unit can create and develop business for each other to form efficiency and cost structure.
China Health Group serves most of the top 50 domestic pharmaceutical companies who license out or co-develop our product commercialization. Our customers also involve a number of overseas companies, located in Europe, North America, Asia, and Africa. Currently, our clients mainly includes Alpharma, GSK, Daewoong, Ranbaxy, Wockhardt, CFM S.p.a., Degussa, Biochemie, Novartis, Heber Biotech, Fako, etc.